The efficacy of treatment of addition in Alzheimer’s disease: rationale for combination therapy with galantamine and memantine

Author(s):  
Julio Zarra
2015 ◽  
Vol 6 (1) ◽  
pp. 55-57 ◽  
Author(s):  
Daniel Kamp ◽  
Myrella Paschali ◽  
Tillmann Supprian ◽  
Christian Lange-Asschenfeldt

2016 ◽  
Vol 12 (5) ◽  
pp. 623-630 ◽  
Author(s):  
James A. Hendrix ◽  
Randall J. Bateman ◽  
H. Robert Brashear ◽  
Cynthia Duggan ◽  
Maria C. Carrillo ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Tadashi Kanamori ◽  
Yoshiyuki Kaneko ◽  
Kouju Yamada ◽  
Masahiro Suzuki

Pica in Alzheimer's disease (AD) makes it difficult for caregivers to provide care. However, few effective medications have been reported for pica in AD. We report a case of AD with pica that was successfully improved by trazodone and fluvoxamine. An 80-year-old woman with AD was admitted to our hospital due to aggravated pica, including eating weeds in the facility's garden and eating a dishwashing sponge. Her pica was accompanied by oral tendency, prosopagnosia, and placidity. She took rivastigmine and memantine, but these were ineffective for her pica. She was given olanzapine and perospirone, but both were discontinued due to over-sedation and severe extrapyramidal symptoms, respectively. We then administered trazodone and fluvoxamine, both of which have demonstrated effectiveness for pica in frontotemporal dementia (FTD). Her pica behaviors then disappeared without daytime sleepiness. In this case, pica with oral tendency, which was accompanied by prosopagnosia and placidity, may be interpreted as a partial symptom of Klüver–Bucy syndrome (KBS). KBS is often seen in FTD, but also occurs in late-stage AD. Our case together with previous reports showing that trazodone and fluvoxamine were effective for pica in FTD suggest that the same common drug therapy may be successful in pica with oral tendency, regardless of the subtype of dementia.


2011 ◽  
Vol 6 (4) ◽  
pp. 228
Author(s):  
José L Molinuevo ◽  

Two effective symptomatic therapies are available for Alzheimer’s disease: the cholinesterase inhibitors (ChEIs) and memantine, an N-methyl-D-aspartate receptor antagonist. Current data demonstrate that combination therapy with memantine and a ChEI produces symptomatic benefits in all domains of AD. The benefits of combination therapy are greater than those of ChEI monotherapy, are sustained long term and appear to increase with time.


2020 ◽  
Vol 143 ◽  
pp. 109879
Author(s):  
Sukriti Vishwas ◽  
Ankit Awasthi ◽  
Leander Corrie ◽  
Sachin Kumar Singh ◽  
Monica Gulati

2007 ◽  
Vol 3 (3S_Part_3) ◽  
pp. S162-S163
Author(s):  
Joshua Shua-Haim ◽  
Dorina Hajnaj ◽  
Syed Zaidi ◽  
Paul Lee ◽  
Avraham Tuvy

Author(s):  
F. Jessen

Over the last several years, many clinical trials in Alzheimer’s disease (AD) have failed and in those with a positive signal, the effect size was of limited magnitude. It has become clear that the molecular mechanisms, which underlie neuronal damage and clinical worsening in AD are complex; maybe even too complex to be sufficiently impacted upon by a single molecular target approach. As in many other diseases, combination therapy might be a way forward to in achieve effects, which eventually are large enough to robustly prove efficacy and to provide patient related benefit.


2014 ◽  
Vol 15 (1) ◽  
pp. 107-113 ◽  
Author(s):  
Diane Stephenson ◽  
Dan Perry ◽  
Cynthia Bens ◽  
Lisa J Bain ◽  
Donald Berry ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document